Short answer
Aquestive Therapeutics, Inc. (AQST) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Investor presentation disclosed under Regulation FD for institutional investor and analyst meetings.
Aquestive Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Investor presentation disclosed under Regulation FD for institutional investor and analyst meetings
- Presentation likely contains current strategic, pipeline, or financial updates, with details in Exhibit 99.1
- Investors should monitor subsequent filings for amended or updated information
Item EX-99.1 · Exhibit EX-99.1
- Anaphylm NDA resubmission accepted, with FDA PDUFA goal date March 16, 2027
- Regulatory catalyst remains binary: FDA may approve, request additional information, or issue another rejection
- Cash $90.3M as of September 30, 2026, plus potential $75M strategic funding and $20M debt access, both conditionally available
- Pipeline opportunity includes potential peak annual sales above $1B for Anaphylm, above $500M for AQST-108, and above $100M Libervant sales
- Canada filing targeted by year-end 2026 and European Union filing in Q1 2027, expanding potential regulatory catalysts beyond the U.S.
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aquestive Therapeutics, Inc. 8-K filings
Get the next AQST 8-K as it lands
Follow AQST for push alerts, or ask the research agent what this filing means.